ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares
Stephen Davis, the CEO of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), has sold 17,714 shares of the company on March 27, 2024, according to a recent SEC filing. The transaction was executed at an average price of $17.9 per share, resulting in a total value of $316,880.60.
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company has a portfolio of products aimed at a range of conditions including Parkinson's disease psychosis, schizophrenia, and major depressive disorder.
Over the past year, the insider has sold a total of 266,576 shares of ACADIA Pharmaceuticals Inc and has not made any purchases of the stock. The recent sale by the CEO is part of a series of insider transactions for the company. In the past year, there has been a total of 1 insider buy and 35 insider sells for ACADIA Pharmaceuticals Inc.
On the date of the insider's recent sale, shares of ACADIA Pharmaceuticals Inc were trading at $17.9, giving the company a market capitalization of $2.998 billion.
The stock's price-to-GF-Value ratio stands at 0.57, indicating that ACADIA Pharmaceuticals Inc is significantly undervalued based on its GF Value of $31.67. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which factors in historical trading multiples, a GuruFocus adjustment factor based on the company's past performance, and future business performance estimates from Morningstar analysts.
The insider trend image above reflects the recent insider selling activity for ACADIA Pharmaceuticals Inc.
The GF Value image provides a visual representation of the stock's current valuation in relation to its GuruFocus Value.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
